Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Daratumumab + Teclistamab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Daratumumab||Darzalex||JNJ-54767414||CD38 Antibody 17||Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov).|
|Teclistamab||Tecvayli||JNJ-64007957|BCMAxCD3|JNJ 64007957|JNJ64007957||CD3 Antibody 74 TNFRSF17 Antibody 14||Tecvayli (teclistamab) is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668). Tecvayli (teclistamab) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04108195||Phase I||Daratumumab + Teclistamab Daratumumab + Talquetamab||A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma||Active, not recruiting||USA | ESP | DEU | CAN||1|
|NCT05083169||Phase III||Bortezomib + Daratumumab + Dexamethasone Daratumumab + Teclistamab Daratumumab + Dexamethasone + Pomalidomide||A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)||Recruiting||USA | ITA | FRA | ESP | DEU | CAN | BEL||14|